Randomized trial shows reduced cardiovascular events in intermediate-risk individuals through rosuvastatin treatment, suggesting potential benefits for this population.
Treatment with rosuvastatin at a dose of 10 mg per day resulted in a significantly lower risk of cardiovascular events than placebo in an intermediate-risk, ethnically diverse population without cardiovascular disease. (Funded by the Canadian Institutes of Health Research and AstraZeneca; HOPE-3 ClinicalTrials.gov number, NCT00468923.).
No takes yet. Share an insight, caveat, or question.
Yusuf et al. (2016) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: